0002001011-24-000053.txt : 20240517
0002001011-24-000053.hdr.sgml : 20240517
20240517195950
ACCESSION NUMBER: 0002001011-24-000053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240515
FILED AS OF DATE: 20240517
DATE AS OF CHANGE: 20240517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Espinoza Octavio
CENTRAL INDEX KEY: 0001905248
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24962079
MAIL ADDRESS:
STREET 1: C/O LIGAND PHARMACEUTICALS INC
STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-05-15
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001905248
Espinoza Octavio
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-05-15
4
S
0
5873
86.012
D
23882
D
Common Stock
2024-05-16
4
S
0
2264
86.0034
D
21618
D
Common Stock
2024-05-17
4
M
0
206
57.22
A
21824
D
Common Stock
2024-05-17
4
M
0
1544
63.62
A
23368
D
Common Stock
2024-05-17
4
M
0
145
68.74
A
23513
D
Common Stock
2024-05-17
4
M
0
5022
52.84
A
28535
D
Common Stock
2024-05-17
4
S
0
5022
86.6652
D
23513
D
Common Stock
2024-05-17
4
S
0
134
86.6497
D
23379
D
Employee Stock Option (right to buy)
57.22
2024-05-17
4
M
0
206
0.0
D
2030-10-01
Common Stock
206
7516
D
Employee Stock Option (right to buy)
63.62
2024-05-17
4
M
0
1544
0.0
D
2032-12-13
Common Stock
1544
18456
D
Incentive Stock Option (right to buy)
68.74
2024-05-17
4
M
0
145
0.0
D
2029-02-11
Common Stock
145
0
D
Non-Qualified Stock Option (right to buy)
52.84
2024-05-17
4
M
0
5022
0.0
D
2032-05-05
Common Stock
5022
16179
D
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.
The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023.
The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
2024-05-17